Loading...
BVMF
HYPE3
Market cap2.95bUSD
Dec 05, Last price  
25.35BRL
1D
-8.05%
1Q
8.10%
Jan 2017
-2.99%
IPO
216.08%
Name

Hypera SA

Chart & Performance

D1W1MN
BVMF:HYPE3 chart
P/E
11.97
P/S
2.16
EPS
2.12
Div Yield, %
3.08%
Shrs. gr., 5y
-0.06%
Rev. gr., 5y
17.70%
Revenues
7.44b
-5.97%
346,700,000380,267,0001,061,500,0001,332,994,0002,025,272,0003,159,728,0003,324,630,0003,873,683,0004,258,740,0004,680,348,0002,956,649,0003,288,747,0003,638,458,0003,724,309,0003,294,749,0004,088,871,0005,937,373,0007,546,355,0007,914,658,0007,442,466,000
Net income
1.34b
-18.63%
31,000,000-2,932,00042,100,000-207,876,000313,373,000261,901,000-54,651,000203,913,000256,722,000402,695,000559,872,0001,174,574,000964,942,0001,129,601,0001,164,040,0001,295,116,0001,330,208,0001,696,697,0001,647,960,0001,340,990,000
CFO
2.54b
+5.99%
85,262,000193,504,00067,236,000580,234,000713,805,000665,785,000664,001,000323,692,000881,756,000932,612,0001,066,494,000823,882,0001,183,054,0001,399,131,0002,038,793,0002,395,993,0002,539,599,000
Dividend
Sep 24, 20240.19534 BRL/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Hypera S.A. operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, MaxSulid, milgamma, Mioflex – A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands. The company also provides dermo-cosmetics products under the Mantecorp Skincare brands; and consumer health products under the Apracur, Benegrip, Coristina d, Engov, Epocler, Estomazil, and other brands. In addition, it offers nutritional and vitamin supplement products under the Tamarine, Vitasay, Biotônico Fontoura, and Zero-Cal brands; and similar and generic medicines under the Neo Química, Sodium Diclofenac, Hydroxyzine, Dipyron, Ibuprofen, Losartan Potassium, Mal Dexchlorpheniramine, Naproxene, Paracetamol, Simethicon, Loratadine, Omeprazole, Tadalaphyl, and Desogestrel brand names. The company was formerly known as Hypermarcas S.A. and changed its name to Hypera S.A. in February 2018. Hypera S.A. is based in São Paulo, Brazil.
IPO date
Apr 16, 2008
Employees
9,000
Domiciled in
BR
Incorporated in
BR

Valuation

Title
BRL in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT